Mirum Pharmaceuticals (MIRM) director receives deferred stock units and options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Mirum Pharmaceuticals director Patrick J. Heron received new equity awards as part of his compensation. He was granted 1,980 deferred stock units and 3,772 stock options, each option giving the right to buy one share of common stock at an exercise price of $101.00 per share.
The stock options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service. These are grants and not open‑market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Heron Patrick J
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 3,772 | $0.00 | -- |
| Grant/Award | Deferred Stock Units | 1,980 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 3,772 shares (Direct, null);
Deferred Stock Units — 1,980 shares (Direct, null)
Footnotes (1)
- The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Key Figures
Deferred stock units granted: 1,980 units
Stock options granted: 3,772 options
Option exercise price: $101.00 per share
+3 more
6 metrics
Deferred stock units granted
1,980 units
Award to director Patrick J. Heron
Stock options granted
3,772 options
Award to director Patrick J. Heron
Option exercise price
$101.00 per share
Stock Option (right to buy) grant
Option expiration date
June 14, 2036
Expiration of stock option grant
Shares underlying DSUs
1,980 shares
Each DSU represents one common share
Shares underlying options
3,772 shares
Each option for one common share
Key Terms
Deferred Stock Units, Stock Option (right to buy), change in control, separation from service
4 terms
Deferred Stock Units financial
"Each deferred stock unit represents a contingent right to receive one share"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of $101.0000"
change in control financial
"paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
separation from service financial
"within 60 days following separation from service with the Issuer"
FAQ
What insider transactions did Mirum Pharmaceuticals (MIRM) report for Patrick J. Heron?
Mirum reported that director Patrick J. Heron received equity awards, including 1,980 deferred stock units and 3,772 stock options. These awards are part of his compensation and do not represent open-market share purchases or sales.
How many deferred stock units did Patrick J. Heron receive from Mirum Pharmaceuticals (MIRM)?
Patrick J. Heron received 1,980 deferred stock units. Each unit represents a contingent right to one share of Mirum common stock, subject to vesting conditions and payout triggers described in the award terms.
What are the terms of Patrick J. Heron’s stock options at Mirum Pharmaceuticals (MIRM)?
Heron was granted 3,772 stock options with an exercise price of $101.00 per share, expiring on June 14, 2036. The options vest on the first anniversary of the grant date or will be fully vested by Mirum’s 2027 annual stockholder meeting.
When do Patrick J. Heron’s deferred stock units at Mirum Pharmaceuticals (MIRM) vest and pay out?
The deferred stock units vest on the first anniversary of the grant date, or fully by the 2027 annual stockholder meeting. Once vested, they are paid in common stock upon a change in control or within 60 days after separation from service.
Do Patrick J. Heron’s Form 4 transactions for Mirum Pharmaceuticals (MIRM) involve buying or selling shares on the market?
The reported transactions are equity grants, not open-market trades. They consist of awarded deferred stock units and stock options granted at no purchase price, reflecting compensation rather than discretionary buying or selling.